Common options include: Exenatide (Byetta): Two times a day injection Liraglutide (Victoza, Saxenda): Daily injection Dulaglutide (Trulicity): Weekly injection Semaglutide (Ozempic, Rybelsus, Wegovy): Weekly injection or daily pill Tirzepatide (Mounjaro, Zepbound): Weekly injection
"Similar to other incretin-based therapies" with an important caveat: The NEJM paper compares the effect broadly to other GLP-1 drugs
In the weeks leading up to the release of authorised generics, the regulator increased inspections at online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics
Sohum S, AP, MF, MM, AR, RS, Siddharth S, and BLW: Writingreview & editing
Results from double-blind, placebo-controlled trials have recently been published [99,100,101]